NorthRock Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $597K | Buy |
24,805
+726
| +3% | +$19K | 0.01% | 401 |
|
|
2026
Q1 | $676K | Buy |
24,079
+3,246
| +16% | +$86.4K | 0.01% | 366 |
|
|
2025
Q4 | $519K | Sell |
20,833
-55,645
| -73% | -$1.4M | 0.01% | 362 |
|
|
2025
Q3 | $1.95M | Buy |
76,478
+9,827
| +15% | +$243K | 0.04% | 215 |
|
|
2025
Q2 | $1.62M | Buy |
66,651
+18,323
| +38% | +$427K | 0.04% | 161 |
|
|
2025
Q1 | $1.22M | Sell |
48,328
-1,822
| -4% | -$47.7K | 0.04% | 178 |
|
|
2024
Q4 | $1.33M | Sell |
50,150
-20,314
| -29% | -$551K | 0.04% | 164 |
|
|
2024
Q3 | $2.04M | Buy |
70,464
+5,392
| +8% | +$157K | 0.07% | 124 |
|
|
2024
Q2 | $1.82M | Buy |
65,072
+778
| +1% | +$21.4K | 0.07% | 121 |
|
|
2024
Q1 | $1.78M | Buy |
64,294
+3,996
| +7% | +$111K | 0.07% | 134 |
|
|
2023
Q4 | $1.74M | Buy |
60,298
+27,039
| +81% | +$817K | 0.07% | 134 |
|
|
2023
Q3 | $1.1M | Buy |
33,259
+3,281
| +11% | +$116K | 0.12% | 93 |
|
|
2023
Q2 | $1.1M | Buy |
29,978
+2,178
| +8% | +$84.8K | 0.12% | 81 |
|
|
2023
Q1 | $1.13M | Sell |
27,800
-6,730
| -19% | -$291K | 0.12% | 84 |
|
|
2022
Q4 | $1.77M | Buy |
34,530
+108
| +0.3% | +$5.18K | 0.2% | 55 |
|
|
2022
Q3 | $1.51M | Sell |
34,422
-3,994
| -10% | -$194K | 0.18% | 61 |
|
|
2022
Q2 | $2.01M | Buy |
38,416
+2,687
| +8% | +$137K | 0.21% | 50 |
|
|
2022
Q1 | $1.85M | Buy |
35,729
+2,544
| +8% | +$132K | 0.17% | 63 |
|
|
2021
Q4 | $1.96M | Buy |
33,185
+6,079
| +22% | +$301K | 0.15% | 63 |
|
|
2021
Q3 | $1.17M | Sell |
27,106
-3,959
| -13% | -$175K | 0.1% | 84 |
|
|
2021
Q2 | $1.22M | Sell |
31,065
-5,836
| -16% | -$227K | 0.1% | 74 |
|
|
2021
Q1 | $1.34M | Buy |
36,901
+13,107
| +55% | +$465K | 0.12% | 67 |
|
|
2020
Q4 | $876K | Sell |
23,794
-4,606
| -16% | -$169K | 0.09% | 84 |
|
|
2020
Q3 | $989K | Buy |
28,400
+6,869
| +32% | +$241K | 0.11% | 79 |
|
|
2020
Q2 | $668K | Buy |
21,531
+4,885
| +29% | +$166K | 0.08% | 100 |
|
|
2020
Q1 | $515K | Sell |
16,646
-19,537
| -54% | -$666K | 0.07% | 107 |
|
|
2019
Q4 | $1.34M | Buy |
36,183
+6,819
| +23% | +$243K | 0.14% | 88 |
|
|
2019
Q3 | $1M | Buy |
+29,364
| New | +$1.07M | 0.14% | 85 |
|
|
2019
Q1 | – | Sell |
-8,846
| Closed | -$365K | – | 103 |
|
|
2018
Q4 | $365K | Buy |
+8,846
| New | +$367K | 0.11% | 52 |
|
Other funds holding PFE
NorthRock Partners's PFE Position: Q2 2026 in Review
NorthRock Partners increased its Pfizer (PFE) stake by 3% in Q2 2026, buying an estimated $19K and bringing the position to 24,805 shares worth $597K. The position accounts for 0.01% of the portfolio, ranked #401.
NorthRock Partners first reported a position in PFE in Q4 2018 and has held it in 29 quarters since. The position peaked at $2.04M in Q3 2024. 2,839 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- NorthRock Partners held 24,805 shares of Pfizer worth $597K as of Q2 2026.
- NorthRock Partners bought 726 Pfizer shares in Q2 2026, an estimated $19K.
- Pfizer made up 0.01% of NorthRock Partners's portfolio in Q2 2026, its #401 holding.
- NorthRock Partners first reported a position in Pfizer in Q4 2018 and has held it in 29 quarters since.
- NorthRock Partners's Pfizer position peaked at $2.04M in Q3 2024.
- 2,839 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on NorthRock Partners's 13F filing for Q2 2026, filed 11 Aug 2026.